BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 32330622)

  • 1. Severe Radiation Necrosis Refractory to Surgical Resection in Patients with Melanoma and Brain Metastases Managed with Ipilimumab/Nivolumab and Brain-Directed Stereotactic Radiation Therapy.
    Shi DD; Arnaout O; Bi WL; Buchbinder EI; Cagney DN; Insco ML; Liu D; Schoenfeld JD; Aizer AA
    World Neurosurg; 2020 Jul; 139():226-231. PubMed ID: 32330622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity.
    Minniti G; Anzellini D; Reverberi C; Cappellini GCA; Marchetti L; Bianciardi F; Bozzao A; Osti M; Gentile PC; Esposito V
    J Immunother Cancer; 2019 Apr; 7(1):102. PubMed ID: 30975225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
    Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination ipilimumab and radiosurgery for brain metastases: tumor, edema, and adverse radiation effects.
    Diao K; Bian SX; Routman DM; Yu C; Kim PE; Wagle NA; Wong MK; Zada G; Chang EL
    J Neurosurg; 2018 Dec; 129(6):1397-1406. PubMed ID: 29303446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic radiosurgery and ipilimumab for patients with melanoma brain metastases: clinical outcomes and toxicity.
    Diao K; Bian SX; Routman DM; Yu C; Ye JC; Wagle NA; Wong MK; Zada G; Chang EL
    J Neurooncol; 2018 Sep; 139(2):421-429. PubMed ID: 29696531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.
    Long GV; Atkinson V; Lo S; Sandhu S; Guminski AD; Brown MP; Wilmott JS; Edwards J; Gonzalez M; Scolyer RA; Menzies AM; McArthur GA
    Lancet Oncol; 2018 May; 19(5):672-681. PubMed ID: 29602646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma.
    Fang P; Jiang W; Allen P; Glitza I; Guha N; Hwu P; Ghia A; Phan J; Mahajan A; Tawbi H; Li J
    J Neurooncol; 2017 Jul; 133(3):595-602. PubMed ID: 28500560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition.
    Blake Z; Marks DK; Gartrell RD; Hart T; Horton P; Cheng SK; Taback B; Horst BA; Saenger YM
    J Immunother Cancer; 2018 Apr; 6(1):25. PubMed ID: 29622046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes of melanoma brain metastases treated with nivolumab and ipilimumab alone versus nivolumab and ipilimumab with stereotactic radiosurgery.
    Tang JD; Mills MN; Nakashima J; Dohm AE; Khushalani NI; Forsyth PA; Vogelbaum MA; Wuthrick EJ; Yu HM; Oliver DE; Liu JKC; Ahmed KA
    J Neurooncol; 2024 Feb; 166(3):431-440. PubMed ID: 38310157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab.
    Cohen-Inbar O; Shih HH; Xu Z; Schlesinger D; Sheehan JP
    J Neurosurg; 2017 Nov; 127(5):1007-1014. PubMed ID: 28059663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.
    Tan I; Malinzak M; Salama AKS
    J Immunother Cancer; 2018 Jul; 6(1):77. PubMed ID: 30064495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients.
    Amaral T; Kiecker F; Schaefer S; Stege H; Kaehler K; Terheyden P; Gesierich A; Gutzmer R; Haferkamp S; Uttikal J; Berking C; Rafei-Shamsabadi D; Reinhardt L; Meier F; Karoglan A; Posch C; Gambichler T; Pfoehler C; Thoms K; Tietze J; Debus D; Herbst R; Emmert S; Loquai C; Hassel JC; Meiss F; Tueting T; Heinrich V; Eigentler T; Garbe C; Zimmer L;
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammation Flare and Radiation Necrosis Around a Stereotactic Radiotherapy-Pretreated Brain Metastasis Site After Nivolumab Treatment.
    Furuta H; Yoshida T; Natsume A; Hida T; Yatabe Y
    J Thorac Oncol; 2018 Dec; 13(12):1975-1978. PubMed ID: 30017830
    [No Abstract]   [Full Text] [Related]  

  • 14. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
    Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; GĂ©rard CL; Wicky A; Bourhis J; Michielin O
    J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review.
    McDonald MA; Sanghvi P; Bykowski J; Daniels GA
    BMC Cancer; 2018 May; 18(1):549. PubMed ID: 29743050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy.
    Ahmed KA; Stallworth DG; Kim Y; Johnstone PA; Harrison LB; Caudell JJ; Yu HH; Etame AB; Weber JS; Gibney GT
    Ann Oncol; 2016 Mar; 27(3):434-41. PubMed ID: 26712903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1 Dose Escalation Trial of Ipilimumab and Stereotactic Body Radiation Therapy in Metastatic Melanoma.
    Sundahl N; De Wolf K; Kruse V; Meireson A; Reynders D; Goetghebeur E; Van Gele M; Speeckaert R; Hennart B; Brochez L; Ost P
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):906-915. PubMed ID: 29485070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic Control.
    Alvarez-Breckenridge C; Giobbie-Hurder A; Gill CM; Bertalan M; Stocking J; Kaplan A; Nayyar N; Lawrence DP; Flaherty KT; Shih HA; Oh K; Batchelor TT; Cahill DP; Sullivan R; Brastianos PK
    Oncologist; 2019 May; 24(5):671-679. PubMed ID: 30796152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiosurgery/stereotactic radiotherapy in combination with immunotherapy and targeted agents for melanoma brain metastases.
    Trino E; Mantovani C; Badellino S; Ricardi U; Filippi AR
    Expert Rev Anticancer Ther; 2017 Apr; 17(4):347-356. PubMed ID: 28277101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery.
    Mathew M; Tam M; Ott PA; Pavlick AC; Rush SC; Donahue BR; Golfinos JG; Parker EC; Huang PP; Narayana A
    Melanoma Res; 2013 Jun; 23(3):191-5. PubMed ID: 23462208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.